Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens: A multicenter, randomized, crossover phase 3 study

Anti-Cancer Drugs

Volumn 24, Issue 6, 2013, Pages 641-647

  Shi, Yuan Kai ^a   Chen, Qiang ^e   Zhu, Yun Zhong ^b   He, Xiao Hui ^a   Wang, Hua Qing ^f   Jiang, Ze Fei ^c   Chang, Jian Hua ^h   Liu, Yun Peng ^j   Wang, An Lan ^k   Luo, De Yun ^l   Zhang, Yang ^m   Ke, Xiao Yan ^d   Li, Wei Lian ^g   Zhang, Wei Jing ^c   Wang, Xiu Wen ⁿ   Zhang, Yi Ping ^o   Wang, Jian Min ⁱ   Liu, Xiao Qing ^c  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c Beijing 307 Hospital   (China)

^d PEKING UNIVERSITY THIRD HOSPITAL   (China)

^e FUJIAN PROVINCIAL CANCER HOSPITAL   (China)

^f TIANJIN MEDICAL UNIVERSITY   (China)

^g TIANJIN PEOPLE'S HOSPITAL   (China)

^h FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

ⁱ SECOND MILITARY MEDICAL UNIVERSITY   (China)

^j CHINA MEDICAL UNIVERSITY   (China)

^k HUNAN CANCER HOSPITAL   (China)

^l SICHUAN UNIVERSITY   (China)

^m DALIAN MEDICAL UNIVERSITY   (China)

ⁿ SHANDONG UNIVERSITY   (China)

^o ZHEJIANG CANCER HOSPITAL   (China)

more..

Author keywords

chemotherapy; clinical trial; filgrastim; neutropenia; polyethylene glycol

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NEUTROPHIL COUNT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CROSS-OVER STUDIES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; NEUTROPENIA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS;

EID: 84878943729     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283610b5d     Document Type: Article

References (17)

1. Renwick W, Pettengell R, Green M. Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience. BioDrugs 2009; 23:175-186.
2. Fortner BV, Schwartzberg L, Tauer K, Houts AC, Hackett J, Stolshek BS. Impact of chemotherapy-induced neutropenia on quality of life: a prospective pilot investigation. Support Care Cancer 2005; 13:522-528. (Pubitemid 40933609)
3. Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, et al. A randomized double-blind multicenter phase III study of fixed-dose singleadministration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14:29-35. (Pubitemid 36150255)
4. Holmes FA, O'Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20:727-731. (Pubitemid 34111380)
5. Di Lorenzo G, D'Aniello C, Buonerba C, Federico P, Rescigno P, Puglia L, et al. Peg-filgrastim and cabazitaxel in prostate cancer patients. Anticancer Drugs 2013; 24:84-89.
6. Shi YK, He XH, Yang S, Wang HQ, Jiang ZF, Zhu YZ, et al. Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study. Zhonghua Yi Xue Za Zhi 2006; 86:3414-3419. (Pubitemid 46344153)
7. Shi YK, Liu P, Yang S, Han XH, He XH, Ai B, et al. Phase I clinical trial of intravenous pegylated recombinant human granulocyte colony-stimulating factor. Ai Zheng 2006; 25:495-500.
8. Ozer H, Mirtsching B, Rader M, Luedke S, Noga SJ, Ding B, et al. Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Oncologist 2007; 12:484-494. (Pubitemid 46698726)
9. Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebocontrolled phase III study. J Clin Oncol 2005; 23:1178-1184. (Pubitemid 46202274)
10. Von Minckwitz G, Blohmer JU, Löhr A, Raab G, Eidtmann H, Gerber B, et al. Primary prophylaxis with 3 weekly pegfilgrastim and ciprofloxacin effectively prevent (febrile) neutropenia and infection during neoadjuvant chemotherapy with docetaxel/doxorubicin/cyclophosphamide (TAC) in breast cancer patients [abstract]. J Clin Oncol 2005; 23:8008.
11. Cleophas TJ, de Vogel EM. Crossover studies are a better format for comparing equivalent treatments than parallel-group studies. Pharm World Sci 1998; 20:113-117. (Pubitemid 28204305)
12. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991; 133:144-153.
13. Grigg A, Solal-Celigny P, Hoskin P, Taylor K, McMillan A, Forstpointner R, et al. Open-label, randomized study of pegfilgrastim versus daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44:1503-1508. (Pubitemid 36833963)
14. Intragumtornchai T, Sutheesophon J, Sutcharitchan P, Swasdikul D. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2000; 37:351-360. (Pubitemid 30162545)
15. Kitay-Cohen Y, Lishner M, Shelef A, Ravid M, Manor Y. Bone marrow involvement, in intensively treated patients with intermediate grade non- Hodgkin's lymphoma, is a risk factor for granulocytopenia and fever. Leuk Lymphoma 1996; 20:333-336. (Pubitemid 126714889)
16. Layton JE, Hockman H, Sheridan WP, Morstyn G. Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood 1989; 74:1303-1307. (Pubitemid 19227439)
17. Nicola NA, Peterson L, Hilton DJ, Metcalf D. Cellular processing of murine colony-stimulating factor (Multi-CSF, GM-CSF, G-CSF) receptors by normal hemopoietic cells and cell lines. Growth Factors 1988; 1:41-49. (Pubitemid 19144094)